FNIH 2023 HEALTH IMPACT REPORTBUILDING BRIDGES TO BREAKTHROUGHS

Message from Leadership

Sickle Cell Disease

Bespoke Gene Therapy Consortium

NIMBLE

Pediatric Devices

Alzheimer’s Disease

A-PLUS Trial

Pandemic Preparedness

GeneConvene

Lurie Prize

Partnership Award

Trailblazer Prize

Fellowships, Lectures & Training Programs

Patients First

Patient Voice

2023 Benefactors

2023 Board of Directors

Facts & Figures

Financials

• Message from Leadership

  

  • Julie Gerberding, President and CEO

• Accelerating New Therapies

  

  • Sickle Cell Disease
  • Bespoke Gene Therapy Consortium
  • NIMBLE
  • Pediatric Devices
  • Alzheimer’s Disease

• Advancing Global Health

  

  • A-PLUS Trial
  • Pandemic Preparedness
  • GeneConvene

• Powering Science

  

  • Lurie Prize
  • Trailblazer Prize
  • Partnership Award
  • Fellowships, Lectures & Training Programs

• Patient Engagement

  • Patients First
  • Patient Voices

• People, Facts & Figures

  

  • 2023 Benefactors
  • 2023 Board of Directors
  • Facts & Figures
  • Financials
  • Previous Health Impact Reports